0.06
0.06 (0%)
As of May 18, 2023
Aptinyx Inc. [APTX]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. We focus our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. We believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of our compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system.
| Country | United States |
| Headquarters | evanston, illinois |
| Phone Number | 847-871-0377 |
| Industry | manufacturing |
| CEO | Andrew Kidd |
| Website | www.aptinyx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-20.3 |
| Net Income | $-21.1 |
| Net Cash | $-11.6 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -36.7% |
| Profit as % of Stockholder Equity | -115.4% |
Management Effectiveness
| Return on Equity | -115.4% |
| Return on Assets | -43.9% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $48 |
| Total Liabilities | $29.7 |
| Operating Cash Flow | $-11.4 |
| Investing Cash Flow | |
| Financing Cash Flow | $-0.3 |
